Connect with us

Biotech

Inveready and Gaea Earmark €7 Million to Promote 53Biologics

Through this investment, Gaea and Inveready will support BDI in its organic and inorganic growth, in order to consolidate growth and turn the company into a reference supplier along the entire value chain of mRNA-based therapies, as well as in its consolidation as a research and development (R&D) partner for other companies.

Published

on

Economic support for 53Biologics from Valladolid. Gaea has formalized a joint investment of $8.25 million (€7 million) with Inveready Biotech in Biotechnology Developments for Industry (BDI), head of the BDI group, with the main objective of promoting the growth of its biopharmaceutical subsidiary 53Biologics. This company specializes in the supply of enzymes for mRNA production.

The company was already owned by another vehicle of the management company that remains in the shareholding, Inveready Biotech II, which invested in the launch of the business initiative. The investment provides the company with the necessary resources through tranches to undertake investments to expand its facilities.

Founded in Valladolid in 2011, BDI is a business group dedicated to the development of biotechnological solutions and the development of enzymes and proteins for various industries, highlighting among them the food, industrial, pharmaceutical, diagnostic, and especially those necessary to create mRNA-based drugs.

Read more about the joint investment of Inveready and Gaesa in the biotech company 53Biologics and find the most important business headlines of the day with the Born2Invest mobile app. Don’t waste your time scrolling the internet, our team of seasoned writers will keep you updated with the latest market updates and the most important investments.

Gaea and Inveready will support BDI in its organic and inorganic growth

Through this investment, Gaea and Inveready will support BDI in its organic and inorganic growth, in order to consolidate growth and turn the company into a reference supplier along the entire value chain of mRNA-based therapies, as well as in its consolidation as a research and development (R&D) partner for other companies.

SEE ALSO  Why feasibility studies are crucial when searching for specific types of upcoming projects

Although mRNA-based therapies have only recently become known due to the health crisis caused by COVID-19, it is a technology that has been in development for decades and is applied in a wide range of pathologies, including, in addition to infectious diseases, oncology and immunology.

The effectiveness of COVID-19 in vaccination has meant that the different clinical trials in this field have accelerated, making it necessary to find suppliers of the reagents needed to manufacture this type of drug. Ramón Resa, director of Gaea, commented that “we are very excited to accompany BDI in this new stage of growth, in which we will seek to provide it with the necessary industrial capacity to make it a relevant player in the provision of vaccine enzymes and mRNA-based therapies.”

__

(Featured image by Mathieu Stern via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

Michael Jermaine Cards is a business executive and a financial journalist, with a focus on IT, innovation and transportation, as well as crypto and AI. He writes about robotics, automation, deep learning, multimodal transit, among others. He updates his readers on the latest market developments, tech and CBD stocks, and even the commodities industry. He does management consulting parallel to his writing, and has been based in Singapore for the past 15 years.

Continue Reading